September 11, 2025

5-Fluorouracil (5-FU)-Induced Organ Toxicities: Mechanisms, Management, and Prevention Strategies.

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Study reveals 5-FU-related toxicities in cancer patients, highlighting the role of pharmacogenomic factors in management.

Severe organ toxicities frequently limit the therapeutic potential of 5-fluorouracil in cancer treatment.
Documented toxicity occurrences range from 0.55% to 40%, influenced by individual genetic variations.
Assessment using pharmacogenomic testing may lower the risk of serious toxicities linked to 5-FU treatment.
Management primarily focuses on supportive care and dose modifications to mitigate organ toxicities.

Moghadamnia et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark